Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Lu DSK, Vedantham S, Krasny RM, Kadell B, Berger WL, Reber HA. Two-phase helical CT for pancreatic tumors: pancreatic versus hepatic phase enhancement of tumor, pancreas, and vascular structures.Radiology 1996; 199: 697–701.
O’Malley ME, Boland GW, Wood BJ, Fernandez-del Castillo C, Warshaw AL, Mueller PR. Adenocarcinoma of the head of the pancreas: determination of surgical unresectability with thin-section pancreatic-phase helical CT.Am J Roentgenol 1999; 173: 1513–1518.
Castillo CFD, Rattner DW, Warchaw AL. Further experience with laparoscopy and peritoneal cytology in the staging of pancreatic cancer.Br J Surg 1995; 82: 1127–1129.
John TG, Greig JD, Carter DC, Garden OJ. Carcinoma of the pancreatic head and periampullary region: tumor staging with laparoscopy and laparoscopic ultrasonography.Ann Surg 1995; 221: 156–164.
Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Imamura M, et al. Contribution of PET in the detection of liver metastases from pancreatic tumours.Clinical Radiology 1999; 54: 248–252.
Keogan MT, Tyler D, Clark L, Branch MS, McDermott VG, DeLong DM, et al. Diagnosis of pancreatic carcinoma: Role of FDG PET.Am J Roentgenol 1998; 171: 1565–1570.
Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.J Nucl Med 1999; 40: 1784–1791.
Frohlich A, Diederichs CG, Staib L, Vogel J, Beger HG, Reske SN. Detection of liver metastases from pancreatic cancer using FDGPET. J Nucl Med 1999; 40: 250–255.
Diederichs CG, Staib L, Vogel J, Glasbrenner B, Glatting G, Brambs HJ, et al. Values and limitations ofl8F-fluoro- deoxyglucose-positron-emission tomography with pre-operative evaluation of patients with pancreatic masses.Pancreas 2000; 20: 109–116.
Yasuda S, Shohtsu A. Cancer screening with whole-body18F-fluorodeoxyglucose positron-emission tomography.Lancet 1997; 350: 1819.
Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology.Radiology 2004; 231: 305–332.
Higashi T, Tamaki N, Honda T, Torizuka T, Kimura T, Inokuma T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study.J Nucl Med 1997; 38: 1337–1344.
Higashi T, Tamaki N, Torizuka T, Nakamoto Y, Sakahara H, Kimura T, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors.J Nucl Med 1998; 39: 1727–1735.
Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, et al. Delayedl8F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.Cancer 2000; 89: 2547–2554.
Bakkevold KE, Arnesjo B, Kambestad B. Carcinoma of the pancreas and papilla of vater-assessment of resectability and factors influencing resectability in stage I carcinomas. A prospective multicentre trial in 472 patients.Eur J Surg Oncol 1992; 18: 494–507.
Nakamoto Y, Saga T, Ishimori T, Mamede M, Togashi K, Higuchi T, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer.Am J Roentgenol 2001; 176: 1449–1454.
Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluoro- deoxyglucosein vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography.J Nucl Med 1992; 33: 1972–1980.
Higashi T, Saga T, Nakamoto Y, Ishimori T, Fujimoto K, Doi R, et al. Diagnosis of pancreatic cancer using fluorine-18 fiuorodeoxyglucose positron emission tomography (FDG PET)—usefulness and limitation in clinical reality—.Ann Nucl Med 2003; 17: 261–279.